UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 190

Sortiert nach

Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity

Acta pharmacologica Sinica, 2020-11, Vol.41 (11), p.1395-1402

2020

Link zum Volltext

Verfügbarkeit prüfen

Oncogene-induced senescence: a double edged sword in cancer

Acta pharmacologica Sinica, 2018-10, Vol.39 (10), p.1553-1558

2018

Link zum Volltext

Verfügbarkeit prüfen

PI3K isoform-selective inhibitors： next-generation targeted cancer therapies

Acta pharmacologica Sinica, 2015-10, Vol.36 (10), p.1170-1176

2015

Link zum Volltext

Verfügbarkeit prüfen

CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment

Acta pharmacologica Sinica, 2020-05, Vol.41 (5), p.583-587

2020

Link zum Volltext

Verfügbarkeit prüfen

Toward rapamycin analog (rapalog)-based precision cancer therapy

Acta pharmacologica Sinica, 2015-10, Vol.36 (10), p.1163-1169

2015

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Chemokine (CXC Motif) Ligand 12/Chemokine (CXC Motif) Receptor 4 Axis (CXCL12/CXCR4)-mediated Cell Migration by Targeting Mammalian Target of Rapamycin (mTOR) Pathway in Human Gastric Carcinoma Cells

The Journal of biological chemistry, 2012-04, Vol.287 (15), p.12132-12141

2012

Link zum Volltext

Verfügbarkeit prüfen

PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment

Cancer letters, 2019-09, Vol.459, p.145-155

2019

Link zum Volltext

Verfügbarkeit prüfen

Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma

Cancer letters, 2022-01, Vol.524, p.206-218

2022

Link zum Volltext

Verfügbarkeit prüfen

Xanthine dehydrogenase rewires metabolism and the survival of nutrient deprived lung adenocarcinoma cells by facilitating UPR and autophagic degradation

International journal of biological sciences, 2023, Vol.19 (3), p.772-788

2023

Link zum Volltext

Verfügbarkeit prüfen

Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells

Cell death & disease, 2021-01, Vol.12 (1), p.85-85, Article 85

2021

Link zum Volltext

Verfügbarkeit prüfen

PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e003093

2021

Link zum Volltext

Verfügbarkeit prüfen

The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8

Acta pharmacologica Sinica, 2018-08, Vol.39 (8), p.1338-1346

2018

Link zum Volltext

Verfügbarkeit prüfen

HSP90 inhibitor AUY922 abrogates up‐regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer

International journal of cancer, 2014-11, Vol.135 (10), p.2462-2474

2014

Link zum Volltext

Verfügbarkeit prüfen

Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer

Cancer letters, 2018-10, Vol.433, p.273-282

2018

Link zum Volltext

Verfügbarkeit prüfen

Membrane metallo‐endopeptidase mediates cellular senescence induced by oncogenic PIK3CAH1047R accompanied with pro‐tumorigenic secretome

International journal of cancer, 2019-08, Vol.145 (3), p.817-829

2019

Link zum Volltext

Verfügbarkeit prüfen

SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma

Acta pharmacologica Sinica, 2022-01, Vol.43 (1), p.209-219

2022

Link zum Volltext

Verfügbarkeit prüfen

Polycyclic polyprenylated acylphloroglucinols from Hypericum choisianum

Natural product research, 2021, Vol.35 (2), p.195-202

2021

Link zum Volltext

Verfügbarkeit prüfen

Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening

Acta pharmacologica Sinica, 2020-03, Vol.41 (3), p.423-431

2020

Link zum Volltext

Verfügbarkeit prüfen

New microtubule-inhibiting anticancer agents

Expert opinion on investigational drugs, 2010-03, Vol.19 (3), p.329-343

2010

Link zum Volltext

Verfügbarkeit prüfen

Single-cell RNA sequencing reveals the suppressive effect of PPP1R15A inhibitor Sephin1 in antitumor immunity

iScience, 2023-02, Vol.26 (2), p.105954-105954, Article 105954

2023

Link zum Volltext

Verfügbarkeit prüfen

Protocol for PPP1R15A-inhibited mouse model establishment with subcutaneous B16F1 tumor and single-cell analysis

STAR protocols, 2023-12, Vol.4 (4), p.102616-102616, Article 102616

2023

Link zum Volltext

Verfügbarkeit prüfen

Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species

Cancer biology & therapy, 2008-07, Vol.7 (7), p.1017-1023

2008

Link zum Volltext

Verfügbarkeit prüfen

Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors

European journal of medicinal chemistry, 2020-03, Vol.189, p.112059-112059, Article 112059

2020

Link zum Volltext

Verfügbarkeit prüfen

Dipotassium N-stearoyltyrosinate ameliorated pathological injuries in triple-transgenic mouse model of Alzheimer's disease

Journal of pharmacological sciences, 2016-09, Vol.132 (1), p.92-99

2016

Link zum Volltext

Verfügbarkeit prüfen

S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton

PloS one, 2009-03, Vol.4 (3), p.e4881

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 190

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(170)
Mit Volltextzugriff
(175)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(135)
Life Sciences & Biomedicine
(113)
Humans
(87)
Animals
(45)
Pharmacology & Pharmacy
(42)
Male
(29)
Female
(28)
Cell Line, Tumor
(25)
Physical Sciences
(24)
Antineoplastic Agents - Pharmacology
(23)
Chemistry
(23)
Oncology
(22)
Mice
(21)
Cell Proliferation - Drug Effects
(19)
Chemistry, Multidisciplinary
(19)
Adult
(18)
Apoptosis
(18)
Cancer
(18)
Middle Aged
(16)
Kinases
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity

Oncogene-induced senescence: a double edged sword in cancer

PI3K isoform-selective inhibitors： next-generation targeted cancer therapies

CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment

Toward rapamycin analog (rapalog)-based precision cancer therapy

Inhibition of Chemokine (CXC Motif) Ligand 12/Chemokine (CXC Motif) Receptor 4 Axis (CXCL12/CXCR4)-mediated Cell Migration by Targeting Mammalian Target of Rapamycin (mTOR) Pathway in Human Gastric Carcinoma Cells

PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment

Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma

Xanthine dehydrogenase rewires metabolism and the survival of nutrient deprived lung adenocarcinoma cells by facilitating UPR and autophagic degradation

Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells

PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism

The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8

HSP90 inhibitor AUY922 abrogates up‐regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer

Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer

Membrane metallo‐endopeptidase mediates cellular senescence induced by oncogenic PIK3CAH1047R accompanied with pro‐tumorigenic secretome

SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma

Polycyclic polyprenylated acylphloroglucinols from Hypericum choisianum

Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening

New microtubule-inhibiting anticancer agents

Single-cell RNA sequencing reveals the suppressive effect of PPP1R15A inhibitor Sephin1 in antitumor immunity

Protocol for PPP1R15A-inhibited mouse model establishment with subcutaneous B16F1 tumor and single-cell analysis

Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species

Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors

Dipotassium N-stearoyltyrosinate ameliorated pathological injuries in triple-transgenic mouse model of Alzheimer's disease

S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton

Suchergebnisse filtern